Steven Ruhl, VP of manufacturing for CURE Pharmaceutical, was featured in a roundtable in the April edition of the American Pharmaceutical Review on “Raw Materials and Functional Excipients.”

“Regulatory and quality expectations of excipients will continue to increase,” said Ruhl, “which has put more pressure on excipient and raw material companies to invest in characterizing functionality and building robust processes to consistently address company needs. This has led to a greater focus on understanding critical material attributes and ranges by both suppliers and customers earlier in the development process.”

Read the full article: Raw Materials and Functional Excipients (American Pharmaceutical Review)